Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial

RCT (n=150 in China) reported overall 28-day negative conversion rate was not different between hydroxychloroquine (HCQ) plus standard-of-care (SOC) vs. SOC alone in adult patients with COVID-19 (85.4% vs. 81.3%) but more adverse events were found in HCQ group (30% vs. 8.8%).

MedRxiv